Резултати

eNauka >  Results >  Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial
Title: Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial
Authors Reck, Martin; ...; Andric, Zoran G  ; ...; (broj, koautora 18)
Issue Date: 2024
Publication: JOURNAL OF THORACIC ONCOLOGY
ISSN: 1556-0864 Journal of Thoracic Oncology Search Idenfier
Type: Article
Collation: vol. 19 br. 2 str. 297-313
DOI: 10.1016/j.jtho.2023.09.1445
WoS-ID: 001176202400001
Scopus-ID: 2-s2.0-85176396741
URI: https://enauka.gov.rs/handle/123456789/938672
Project: Healthcare business of Merck KGaA, Darmstadt, Germany
Pfizer
Metadata source: (Preuzeto iz Nasi u WoS)
M-category: 
21a+M21a+

19
SCOPUSTM
1
OpenCitations
17
WEB OF SCIENCETM
Алт метрика
Dimensions
Unpaywall

Резултати на еНаука су заштићени ауторским правима и сва права су задржана, осим ако није другачије назначено.